Little St0cks Sizzle as the Big Ones Fizzle
uprlloh na careertran.com
Neděle Červen 12 15:23:17 CEST 2005
SmallCap BIOTECH Report
<> STEM CELL <> CRYOGENICS <> STEM CELL <>
INVESTING IN EMERGING BIOTECH STOCKS
:: COMPANY SPOTLIGHT ::.
Bio-Matrix Scientific Group Inc.
Driving $75 billion dollar a year Biotechnology and Medical Device
industries is the demand for new products that improve patient
safety, decrease healthcare cost, and most importantly enhance human
Trading Price: $0.94
About Bio-Matrix Scientific Group Inc.:
Bio-Matrix Scientific Group Inc. is a San Diego based development
stage company in the business of medical devices and monitoring
systems research, development and commercialization. Bio-Matrix
Scientific Group Inc. is aligning itself with partners that offer key
technologies in biomedical device development, tissue engineering,
cell culturing, genome therapy and drug delivery systems. Its polymer
coating on medical devices will ensure that cell transference is done
with minimal damage to cells. This should lead to better yields in
stem cell extraction, along with better outcomes for patients in
tissue management procedures.
Recent News: A spokesperson for the Company said that its
Board of Directors plans to spin-off 6,035,501 shares of the common
stock of Frezer, Inc., a wholly owned
subsidiary of Bio-Matrix Scientific Group, to BMXP shareholders of
record as of May 31, 2005.
This represents one share of Frezer, Inc. for every one share of
Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) owned post
"Ground floor" Company Enters Production Phase
Bio-Matrix Scientific Group Inc., announced that Collective
Technologies will manufacture Bio-Matrix's first set of Stem Cell
Devices. The Company anticipates having this set of instruments
sometime within the next two weeks. BMXP also recently finalized
applications for 3 new devices.
This is the first step towards full production of these devices. This
first set of devices will be used for its 510(k) testing, trade shows
and presentations to Physicians and Researchers. "Collective
Technologies enables us to manufacture products in the most efficient
and cost-effective way possible," noted Brian Pockett, Managing
Director and COO of Bio-Matrix Scientific. "We have been impressed by
Collective Technologies' quality record, responsiveness and
flexibility - all of which are critical to our production
objectives." Bio-Matrix sees this event as nearing a point at which
the Company "green-lights" full production of its stem cell and
tissue management instruments.
"REAL DEAL" MANAGEMENT
Philip Watts, Ph.D., the Company's Director of Research and
Development, highly recognized in his field.
James L. Lambert, Ph.D., as its Bio-Instrument Scientific Advisor.
Dr. Lambert specializes in the development of next generation
bio-instrumentation for use in medical research. Dr. Lambert has been
with the Jet Propulsion Laboratory for 17 years, and for the last
five years he has served as the Technical Group Supervisor of the
Intelligent Instrument and Systems Technology Group. Dr. Lambert
leads a multidisciplinary group whose members have advanced degrees
in chemistry, biology, electrical engineering, and computer science.
The charter of the group is to develop advanced in situ instruments
and sensors for NASA and other agencies.
Geoffrey O'Neill, Ph.D. President of the Company. Dr. O'Neill most
recently served as Director of Stem Cell Laboratories and Scientific
Research for Cryo-Cell International Inc. (OTC: CCEL). Cryo-Cell
International represents themselves as the world's largest U-Cord
stem cell banking firm. "The appointment of Dr. O'Neill as President
of Bio-Matrix Scientific Group Inc. signals our Company's aggressive
growth plans in stem cell research devices, biomedical devices and
the continued growth in the development of our Stem Cell Cryogenic
Banks," said Brian Pockett, Managing Director and COO of Bio-Matrix
Stem Cell Cryogenics
Instrumentation for Stem Cell Research and Tissue
Non-Invasive Bio-Systems Monitoring and Measuring Devices
Niche Medical Device Instrumentation
The Company has recently filed a provisional patent application with
the U. S. Patent Office. It anticipates numerous utility patents will
result from this filing.
Bio-Matrix has a four pronged revenue strategy each with a different
trajectory and different inflection points.
The company is spreading its risk over different operating segments
with varying investment requirement and levels of risk.
Larger companies in the medical device industry are aggressive and
smaller companies are always takeover targets.
Potential of BMXP:
The market size of the segments it has chosen to operate in is huge.
The tissue management instruments market size alone is $860 million.
A provisional patent application has already been filed and more are
in the pipeline.
IMPORTANT DISCLAIMER: Information within this email contains "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21B of the Securities Exchange Act
of 1934. Any statements that express or involve discussions with
respect to predictions, goals, expectations, beliefs, plans,
projections, objectives, assumptions or future events or performance
are not statements of historical fact and may be "forward looking
statements." Forward looking statements are based on expectations,
estimates and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through the use of words such as: "projects", "foresee",
"expects", "estimates," "believes," "understands" "will",
"anticipates," or that by statements indicating certain actions
"may," "could," or "might" occur. All information provided within
this email pertaining to investing, stocks,securities must be
understood as information provided and not investment advice.
Emerging Equity Alert advises all readers and subscribers to seek
advice from a registered professional securities representative
before deciding to trade in stocks featured within this email. None
of the material within this report shall be construed as any kind of
investment advice. In compliance with Section 1 we have been
compensated thirty thousand dollars for the dissemination of this
profile.. Be aware of an inherent conflict of interest resulting from
such holdings due to our intent to profit from the liquidation of
these shares. Shares may be sold at any time, even after positive
statements have been made regarding the above company.
Další informace o konferenci Czman